Back

Comparative changes in echocardiographic parameters and NT-proBNP levels after catheter ablation in patients with HF and persistent AF across HF phenotypes

12 April 2026 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Arrhythmias in heart failure Rhythm Control, Catheter Ablation EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Min Su Jung

Keimyung University Hospital Dongsan Medical Center, Daegu (Korea (Republic of))

6 More presentations in this session

Presentation thumbnail
Impact of catheter ablation on ventricular arrhythmias in left ventricular assist device patients: findings from the MUST-LVAD-VT international registry
Doctor Y. Oda (Tsukuba, JP)
Abstract Slides Video
Presentation thumbnail
Nutritional status is linked to disease severity and self-care capacity in patients with chronic heart failure
Associate Professor K. Lomper (Wroclaw, PL)
Abstract Slides Video
Presentation thumbnail
Mechanistic insights into the importance of restoring atrioventricular synchrony in dyssynchronous heart failure patients with atrial fibrillation
Doctor F. de Vere (London, GB)
Abstract Slides Video
Presentation thumbnail
Improvement in quality of life and reduction of hospitalizations in patients with heart failure undergoing cardiac contractility modulation (CCM) therapy: experience from our center
Doctor R. Valecce (Bari, IT)
Presentation thumbnail
Similar incidence of PICM in patients with preserved and moderate range ejection fraction
Doctor S. Howell (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Arrhythmias in heart failure

The Event

Event poster

EHRA 2026

12 April - 14 April 2026
You may be interested in
thumbnail
Congress Session
Atrial fibrillation rhythm control in heart failure patients: what has changed?
thumbnail
Congress Presentation
Catheter ablation for atrial fibrillation in patients with heart failure with preserved ejection fraction
thumbnail
Congress Session
Catheter ablation for atrial fibrillation: relevance of concomitant therapies and comorbidities

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources